Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis
- 1 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Abstract
Summary: Several proton pump inhibitor (PPI) dosing regimens that vary by strength and frequency (once [Qday] or twice [BID] daily) are available to treat gastroesophageal reflux disease (GERD). We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the impact of various PPI regimens on esophageal healing and GERD and heartburn symptoms. To identify relevant studies, we searched EMBASE and PubMed in January 2023, which yielded 1381 records. Eligible RCTs included those that enrolled adults diagnosed with GERD and compared different dosing regimens within the same PPI. The outcomes were esophageal healing and resolution of GERD and heartburn symptoms within 12 weeks (i.e. short-term) and > 12 weeks (i.e. long-term). Meta-analysis pooling of the odds ratios with 95% confidence intervals were estimated using the random-effects inverse-variance model. Overall, a total of 38 RCTs across 20 countries (N = 15,540 patients, mean age 50 years, 55% male) were included. Most PPI trials compared half standard dose Qday versus standard dose Qday or standard dose Qday versus double standard dose Qday. In general, when considering daily dosing, higher PPI strength significantly improved esophageal healing and relief of GERD symptoms both in the short- and long-term. Fewer trials compared Qday versus BID dosing; the impact of BID dosing on outcomes was inconsistent across the different PPI strength comparisons. In conclusion, this meta-analysis revealed that increasing PPI Qday dosages led to improved GERD outcomes. However, few studies compared Qday to BID dosing; as twice daily PPI usage is common in clinical practice, further studies are warranted to determine whether such dosing improves clinical outcomes.Keywords
This publication has 49 references indexed in Scilit:
- Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND studyJournal of Gastroenterology, 2017
- Efficacy of Twice-Daily Rabeprazole for Reflux Esophagitis Patients Refractory to Standard Once-Daily Administration of PPI: The Japan-Based TWICE StudyAmerican Journal of Gastroenterology, 2012
- Double-Dosed Pantoprazole Accelerates the Sustained Symptomatic Response in Overweight and Obese Patients With Reflux Esophagitis in Los Angeles Grades A and BAmerican Journal of Gastroenterology, 2010
- Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux diseaseJournal of Gastroenterology, 2008
- The Economic and Quality-of-Life Impact of Symptomatic Gastroesophageal Reflux DiseaseAmerican Journal of Gastroenterology, 2003
- Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without EsophagitisArchives of internal medicine (1960), 2000
- Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))Digestive Diseases and Sciences, 1998
- The Impact of Gastroesophageal Reflux Disease on Health-related Quality of LifeThe American Journal of Medicine, 1998
- Omeprazole or ranitidine in long-term treatment of reflux esophagitisGastroenterology, 1994
- Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter studyGastroenterology, 1992